Carl Zeiss Meditec/€AFX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Carl Zeiss Meditec
Carl Zeiss Meditec AG, publicly traded under the ticker symbol AFX, specializes in the healthcare technology sector. Founded in 2002 as a spin-off from Carl Zeiss AG, it provides comprehensive medical solutions for ophthalmology and microsurgery. Operating globally, the company combines its expertise in optics, electronics, and precision engineering to offer innovative products that enhance patient care and clinical outcomes.
- Ticker
- €AFX
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 5,798
- Headquarters
- Jena, Germany
AFX Metrics
BasicAdvanced
€3.1B
25.02
€1.39
1.35
€0.55
1.58%
Price and volume
Market cap
€3.1B
Beta
1.35
52-week high
€46.48
52-week low
€22.66
Average daily volume
150K
Dividend rate
€0.55
Financial strength
Total debt to equity
0.276
Interest coverage (TTM)
6.47%
Profitability
EBITDA (TTM)
217.841
Gross margin (TTM)
51.56%
Net profit margin (TTM)
5.57%
Operating margin (TTM)
7.23%
Effective tax rate (TTM)
23.25%
Revenue per employee (TTM)
€380,000
Management effectiveness
Valuation
Price to earnings (TTM)
25.022
Price to revenue (TTM)
1.394
Price to book
1.46
Price to tangible book (TTM)
6.24
Dividend yield (TTM)
1.58%
Forward dividend yield
1.58%
Growth
Revenue change (TTM)
0.07%
Earnings per share change (TTM)
-18.69%
3-year revenue growth (CAGR)
1.60%
10-year revenue growth (CAGR)
7.18%
3-year earnings per share growth (CAGR)
-25.96%
10-year earnings per share growth (CAGR)
3.84%
10-year dividend per share growth (CAGR)
3.77%
What the Analysts think about AFX
Analyst ratings (Buy, Hold, Sell) for Carl Zeiss Meditec stock.
Analyst projections of the future price of Carl Zeiss Meditec stock.
Bulls say / Bears say
Revenue was flat on a currency-adjusted basis over the first nine months, while Microsurgery grew 7.1%. That growth, driven by neurosurgical microscopes, is helping offset weakness in Ophthalmology. (ZEISS)
The ProfitUp programme targets more than €200 million in annual profit improvements by fiscal 2028/29, alongside a return to mid-single-digit growth and an adjusted EBITA margin of around 15%. If delivered, these measures could lift earnings materially from today's weak level. (ZEISS)
Nine-month adjusted EBITA fell to €124.5 million from €177.0 million, and the margin dropped to 8% from 11.1%. Full-year guidance is just €2.15–2.20 billion of revenue and an 8–10% adjusted EBITA margin, leaving the recovery unproven. (ZEISS)
China's volume-based procurement tender weakness forced the withdrawal of a bifocal lens and the return of related inventory, while lower refractive procedure volumes and softer equipment spending also weighed on Ophthalmology. These pressures leave a key business exposed to tender and demand swings. (ZEISS)
Goldman Sachs downgraded the shares to Sell, saying the valuation remains above its 10-year relative range and earnings may not yet have troughed. If estimates fall further, the shares could face more downside despite their recent decline. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2026.
AFX Financial Performance
Revenues and expenses
AFX Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing AFX
AllEURUSDGBP
Fund name | Fund size | €AFX weighting |
|---|---|---|
iShares TecDAX€EXS2 | €645M | 0.94% |
iShares Ageing Population$AGED | $953M | 0.12% |
iShares Ageing Population£AGES | $953M | 0.12% |
iShares Ageing Population€AGED | $903M | 0.12% |
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.08% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.